$0.01
(Market cap
$930 Mln
Recently Viewed
Clear AllMarket cap
$930 Mln
Revenue (TTM)
$14 Mln
P/E Ratio
--
P/B Ratio
12.1
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.4 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
2.7
Debt to Equity
0.1
Book Value
$0.4
EPS
$-0.2
Face value
--
Shares outstanding
196,939,679
CFO
$-552.86 Mln
EBITDA
$-216.25 Mln
Net Profit
$-1,064.11 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Arbutus Biopharma Corp (ABUS)
| -7.8 | 4.6 | 7.1 | 38.2 | 13.9 | 7.2 | -1.3 |
|
BSE Sensex
| -7.3 | 5.3 | -4.1 | -1.1 | 9.6 | 10.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Arbutus Biopharma Corp (ABUS)
| 47.1 | 7.3 | -40.1 | 9.6 | 27.7 | -27.4 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Arbutus Biopharma Corp (ABUS)
|
4.4 | 929.6 | 14.1 | -33.5 | -264.9 | -38.5 | -- | 12.1 |
| 3.7 | 216.4 | 363.3 | -42.5 | 0.1 | -6 | -- | 0.6 | |
| 5.6 | 2,121.3 | 10,309.0 | 155.3 | 17.0 | -17 | 13.5 | 18.8 | |
| 1.2 | 512.0 | 278.4 | -326.6 | -102.3 | -52.4 | -- | 0.9 | |
| 1.6 | 168.6 | 0.0 | -33.8 | -- | -158.8 | -- | 13.0 | |
| 2.8 | 1,034.6 | 193.4 | -9.5 | -8.9 | -0.9 | -- | 0.9 | |
| 0.4 | 2.4 | 54.7 | -11.3 | -16.3 | -516.3 | -- | 0.9 | |
| 1.5 | 205.3 | 279.9 | 18.2 | -4.3 | 4.8 | 13.3 | 0.8 | |
| 3.4 | 18.5 | 0.0 | -26.6 | -- | -289.6 | -- | 2.6 | |
| 3.4 | 18.5 | 0.0 | -26.6 | -- | -289.6 | -- | 2.6 | |
| 1.5 | 391.4 | 946.4 | -15.8 | -1.2 | -1.4 | -- | 0.5 |
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc,... subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania. Read more
Co-Founder, Interim President, CEO & Director
Mr. Michael J. McElhaugh
Co-Founder, Interim President, CEO & Director
Mr. Michael J. McElhaugh
Headquarters
Warminster, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Arbutus Biopharma Corp (ABUS) is $4.44 (NASDAQ) as of 22-Apr-2026 11:39 EDT. Arbutus Biopharma Corp (ABUS) has given a return of 13.92% in the last 3 years.
Since, TTM earnings of Arbutus Biopharma Corp (ABUS) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-27.51
|
12.04
|
|
2024
|
-8.88
|
6.38
|
|
2023
|
-5.78
|
3.97
|
|
2022
|
-5.18
|
2.63
|
|
2021
|
-5.17
|
2.33
|
The 52-week high and low of Arbutus Biopharma Corp (ABUS) are Rs 5.07 and Rs 2.94 as of 22-Apr-2026.
Arbutus Biopharma Corp (ABUS) has a market capitalisation of $ 930 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Arbutus Biopharma Corp (ABUS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.